VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
-
Fulham boss Silva refuses to rule out Saudi switch
-
From Chicago to Chiclayo: Peruvian town hails adoptive son and pope
-
Ivorian women fight FGM with reconstructive surgery
-
Pedersen wins opening stage of Giro d'Italia in Albania
-
Stocks mixed despite hopes for US-China tariff talks
-
US, Swiss agree to speed up tariff talks
-
Trump floats cutting China tariffs to 80% ahead of trade talks
-
Pedersen wins opening stage of Giro d'Italia
-
Marc Marquez sets Le Mans lap record in French MotoGP practice
-
Jungle music: Chimp drumming reveals building blocks of human rhythm
-
Guardiola tells Man City stars to question their hunger after troubled season
-
Putin, Xi, Steven Seagal and missiles: Russia's Red Square parade
-
Trump suggests lower 80% China tariff ahead of Geneva trade talks
-
Arteta wants Arsenal to use Liverpool guard of honour as title fuel
-
Stocks lifted by hopes for US-China talks
-
Putin hails troops in Ukraine as allies attend WWII parade
-
UK, northern European nations support Ukraine 30-day ceasefire: Norway PM
-
Activists hold 'die-in' protest at Soviet monument in Warsaw
-
Trump suggests lower China tariff, says 80% 'seems right!'
-
Alonso confirms exit from Leverkusen at end of season
-
Maresca ready for Chelsea's 'huge' Newcastle test
-
Alcaraz, Sabalenka cruise to wins at the Italian Open
-
Swiss seize window of opportunity on Trump tariffs
-
Amorim admits Man Utd 'problems' despite reaching Europa League final
-
New Pope Leo XIV has mixed record on abuse: campaigners
-
Xabi Alonso confirms exit from Bayer Leverkusen at season's end
-
From blockades to ballots: Serbian students confront government
-
Kyiv's EU allies endorse tribunal to try Russian leaders
-
Two men found guilty of chopping down iconic UK tree
-
Tennis, Twitter and marinated fish: Things to know about Pope Leo
-
Liverpool's Salah voted Football Writers' Player of the Year
-
Pakistan says India has brought neighbours 'closer to major conflict'
-
Stocks lifted by hopes for US-China talks after UK deal
-
Putin hails troops fighting in Ukraine as foreign leaders attend parade
-
Howe urges Newcastle to fulfil Champions League expectation
-
Weary border residents in Indian Kashmir struggle to survive
-
Leo XIV says Church must fight 'lack of faith' in first mass as pope
-
Liverpool boss Slot fears replacing Alexander-Arnold will be a tough task
-
British Airways owner unveils big Boeing, Airbus order
-
IPL suspended for one week over India-Pakistan conflict
-
Slot says all at Liverpool sad to see Alexander-Arnold go
-
Leo XIV celebrates first mass as pope in Sistine Chapel
-
India says repulsed fresh Pakistan attacks as death toll climbs
-
Japan's Panasonic targets 10,000 job cuts worldwide
-
Putin evokes WWII victory to rally Russia behind Ukraine offensive
-
China exports beat forecasts ahead of US tariff talks
-
Leo XIV, the 'Latin Yankee', to celebrate first mass as pope
-
Most stocks lifted by hopes for US-China talks after UK deal
-
IPL suspended indefinitely over India-Pakistan conflict: reports
-
German lender Commerzbank's profits jump as it fends off UniCredit
NYSE - LSE
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
VisiRose Inc. ("VisiRose" or the "Company"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced a $3 million seed financing round for VisiRose. The funds from this round will be directed toward advancing the Company's lead investigational program, particularly facilitating critical regulatory milestones of the clinical development of its therapies for corneal diseases and other severe ocular conditions.
The proceeds from this financing round will support several key initiatives, including:
Completing a pre-investigational new drug (IND) submission meeting with the U.S. Food and Drug Administration (FDA) for VisiRose's Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive, investigational treatment for infectious keratitis and other serious eye infections.
Submitting an IND application for investigational drug PV-305, targeting corneal blindness (RB) through photodynamic therapy (PDAT), and working toward its acceptance by the FDA.
Manufacturing an initial clinical supply of PV-305, enabling the Company to initiate clinical trials, undertake expanded access, and move closer to regulatory approval.
VisiRose is leveraging the novel ocular RB PDAT research from the University of Miami's Bascom Palmer Eye Institute and Ophthalmic Biophysics Center, in collaboration with Provectus Biopharmaceuticals (OTCQB: PVCT). At the heart of the Company's therapeutic platform is Provectus's bioactive synthetic small molecule, Rose Bengal Sodium (RBS), to treat a range of sight-threatening ocular conditions with high unmet medical needs.
"We are pleased to complete this financing round to support the continued progress of our ophthalmology drug pipeline," said Dominic Rodrigues, Acting Chief Executive Officer of VisiRose. "The funding will enable us to advance our lead drug product candidate PV-305 through critical regulatory steps, ultimately moving us closer to providing patients with innovative therapies for corneal diseases and other serious ocular conditions."
Courtesy of Bascom Palmer Eye Institute
About VisiRose
VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.
Contact:
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
[email protected]
For Media Inquiries:
Ira M. Gostin
[email protected]
775-391-0213
SOURCE: VisiRose, Inc.
P.Costa--AMWN
